bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figures S1-S8 from Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition
Authors: Wielgos Monica E. , Zhang Zhuo , Rajbhandari Rajani , Cooper Tiffiny S. , Zeng Ling , Forero Andres , Esteva Francisco J. , Osborne C. Kent , Schiff Rachel , LoBuglio Albert F. , Nozell Susan E. , Yang Eddy S.
Published: April 2023

SFigure1: HER2+ breast cancer cells are sensitive to nirparib SFigure2: HER2+ breast cancer microtumors are sensitive to ABT-888 SFigure3: (A) ABT-888 reduces PAR levels in HER2+ xenograft models. (B) ABT-888 did not cause weight loss in mice SFigure4: Two different PARP-1 siRNAs decrease cell proliferation in HER2+ trastuzumab resistant breast cancer cells. SFigure5: Cell cycle distribution is not affected by PARPi in HER2+ trastuzumab resistant cell lines. SFigure6: IKK protein levels were decreased after treatment with Sigma-Aldrich''s PARP-1 siRNA. SFigure7: PARP-1 and IL-8 gene expression levels after PARP-1 knockdown or inhibition in HER2+ parental and trastuzumab resistant breast cancer cell lines. SFigure8: BRCA2 gene and protein expression levels in BT-474 trastuzumab resistant breast cancer cell lines after PARP-1 knockdown.
Supplemental Figure Legends from Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma
Authors: Patwardhan Parag P. , Musi Elgilda , Schwartz Gary K.
Published: April 2023

Figure legends for supplemental figures
Supplementary Methods from Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance
Authors: Quanz Maria , Bender Eckhard , Kopitz Charlotte , Grünewald Sylvia , Schlicker Andreas , Schwede Wolfgang , Eheim Ashley , Toschi Luisella , Neuhaus Roland , Richter Carmen , Toedling Joern , Merz Claudia , Lesche Ralf , Kamburov Atanas , Siebeneicher Holger , Bauser Marcus , Hägebarth Andrea
Published: April 2023

Supplementary Methods: Synthesis and characterization of BAY-8002; Tritium labeling of AZD3965 and BAY-8002; MCT1 and MCT4 14C-lactate uptake measurements in the X. laevis oocytes expression System
Figure S4 from TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy
Authors: Yano Wakako , Yokogawa Tatsushi , Wakasa Takeshi , Yamamura Keisuke , Fujioka Akio , Yoshisue Kunihiro , Matsushima Eiji , Miyahara Seiji , Miyakoshi Hitoshi , Taguchi Junko , Chong Khoon Tee , Takao Yayoi , Fukuoka Masayoshi , Matsuo Kenichi
Published: April 2023

Expression levels of dUTPase in various tumor xenografts and antitumor efficacy of S-1 and TAS-114 combination in various xenograft models
Supplementary Figures 1-9 from Recombinant MDA-7/IL24 Suppresses Prostate Cancer Bone Metastasis through Downregulation of the Akt/Mcl-1 Pathway
Authors: Pradhan Anjan K. , Bhoopathi Praveen , Talukdar Sarmistha , Shen Xue-Ning , Emdad Luni , Das Swadesh K. , Sarkar Devanand , Fisher Paul B.
Published: April 2023

Supplementary Figure 1: Preliminary study defined optimum dose of MDA-7/IL-24 and the number of injections to achieve a maximum effect with or without BI-97D6 (1.5 mg/kg). Supplementary Figure 2: Effect of MDA-7/IL-24 on normal primary mouse bone marrow cells. Supplementary Figure 3: Effect of His-MDA-7 on osteoclast differentiation. Supplementary Figure 4: Effect of MDA-7/IL-24 on the osteoclastic gene regulation pattern and growth of RAW 264.7 and DU-145 cells. Supplementary Figure 5: Quantification of the Western Blots shown in figure 3 using image J software (n=3). Supplementary Figure 6: Effect of Mcl-1 inhibitors on osteoclast differentiation and effect of MDA-7/IL-24 on the osteoclast differentiation process. Supplementary Figure 7: Effect of Akt and Mcl-1 expression on osteoclast differentiation. Supplementary Figure 8: Western blots showing the downstream signaling cascades in Akt overexpressing stable PC3-ML cells. Clone 1 showed significant up regulation in p-Akt, p-GSK3ÃŽÂ², and cyclin-D1 expression. Supplementary Figure 9: Mice received intra-cardiac injection of PC3-ML luc cells (1 X105) and were treated with recombinant MDA-7 protein (5mg/kg) for 6 doses as described in materials and methods. Mice were imaged by IVIS imaging system.
Supplementary Figure 1 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
Authors: Shimizu Toshihiko , Ishida Joji , Kurozumi Kazuhiko , Ichikawa Tomotsugu , Otani Yoshihiro , Oka Tetsuo , Tomita Yusuke , Hattori Yasuhiko , Uneda Atsuhito , Matsumoto Yuji , Date Isao
Published: April 2023

Glioma cell cytotoxicity with bevacizumab treatment in vitro
Supplementary Figures 1-7 and Supplementary Tables 1-2 from The TLR3 Agonist Inhibit Drug Efflux and Sequentially Consolidates Low-Dose Cisplatin-Based Chemoimmunotherapy while Reducing Side Effects
Authors: Ding Liang , Ren Jing , Zhang Dongya , Li Yi , Huang Xiaofeng , Ji Jianjian , Hu Qingang , Wang Hui , Ni Yanhong , Hou Yayi
Published: April 2023

Supplementary Fig. 1. The expression of TLR3 in OSCC patients; Supplementary Fig. 2. The impacts of poly (I:C) on the vitality of OSCC cells; Supplementary Fig. 3. Poly (I:C) could inhibit the expression of drug transporters; Supplementary Fig. 4. The characteristics of combined chemotherapy in vitro; Supplementary Fig. 5. lnc-IL7R is up-regulated by the combined chemotherapy; Supplementary Fig. 6. Lnc-IL7R knockdown shows weak effects on cell apoptosis and cell cycle; Supplementary Fig. 7. Lnc-IL7R knockdown improves the efficiency of combined chemotherapy; Table 1. information of antibodies and reagents; Table 2. Relationships between TLR3 expression on different cell type and clinicalpathologic Characteristics in OSCC patients.
Supplementary Figures S1-S5 from MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis
Authors: Kim Hee Kyung , Lee InKyoung , Bang Heejin , Kim Hee Cheol , Lee Woo Yong , Yun Seong Hyeon , Lee Jeeyun , Lee Su Jin , Park Young Suk , Kim Kyoung-Mee , Kang Won Ki
Published: April 2023

Supplementary figure S1. siMCT4 knockdown suppressed CRC cell proliferation and protein expression by western blot analysis; Supplementary figure S2. Additive effects of MCT4 inhibition with anti-cancer treatments (chemotherapy or radiotherapy) in other colorectal cancer cell lines (CoLo320, NCI-H716, SW480); Supplementary figure S3. Correlation between hypoxia- or angiogenesis-related factors and MCT4 demonstrated in other colorectal cell lines (HT29, HCT8) using western blot assay; Supplementary figure S4. The decline of VEGF and Angiopoietin 2 were demonstrated in ELISA assay by siHIF1α or siMCT4 in other colorectal cell lines (HT29, HCT8); Supplementary figure S5. Overall Survival according to MCT4 expression by IHC
Supplemental Figure 3 from STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non–Small Cell Lung Cancer
Authors: Njatcha Christian , Farooqui Mariya , Kornberg Adam , Johnson Daniel E. , Grandis Jennifer R. , Siegfried Jill M.
Published: April 2023

Long-Term CS3D treatment alters tumor cellularity
Supplementary Figures from Lack of Constitutively Active DNA Repair Sensitizes Glioblastomas to Akt Inhibition and Induces Synthetic Lethality with Radiation Treatment in a p53-Dependent Manner
Authors: Palanichamy Kamalakannan , Patel Disha , Jacob John R. , Litzenberg Kevin T. , Gordon Nicolaus , Acus Kirstin , Noda Shin-ei , Chakravarti Arnab
Published: April 2023

Supplemental Figure 1. Clonogenic survival and apoptosis assay; Supplemental Figure 2. Apoptosis assay of radiosensitive cells; Supplemental Figure 3. Apoptosis assay of radioresistant cells; Supplemental Figure 4. Apoptosis assay and microscopic images of LN18 and U87 after PIA+RT Annexin-V/PI apoptosis assay was used to assess the cell death of LN18 and U87 cells following PIA and PIA + radiation treatment at the indicated concentrations; Supplemental Figure 5. Growth inhibition of GBM cells after MK2206+RT;Supplemental Figure 6. Intracellular signaling cascades of GBM cells; Supplemental Figure 7. Apoptosis assay of U87-p53 KD cells after PIA+RT Annexin V/PI apoptosis assay in the U87-p53KD 427 construct following the treatments indicated; Supplemental Figure 8. Intracellular signaling cascades of LN18, LN229, U87, U87-p53 KD & GSCs.
Supplementary Figure S4 from Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling
Authors: Inoue Satoshi , Ide Hiroki , Mizushima Taichi , Jiang Guiyang , Netto George J. , Gotoh Momokazu , Miyamoto Hiroshi
Published: April 2023

Effects of NF-κB activation/inhibition on bladder cancer cell growth. MTT assay was performed in: UMUC3 cells cultured in media containing charcoal-stripped FBS (CS-FBS) with ethanol (mock), BA (10 μM), or PAR (10 μM) (A); UMUC3 cells cultured in media containing CS-FBS with DHT (10 nM) and ethanol (mock), BA (10 μM), or PAR (10 μM) (C); UMUC3 cells cultured in media containing normal FBS with ethanol (mock), TNF-α (20 ng/mL), or DHMEQ (10 µg/mL) (E); or UMUC3-control-shRNA or UMUC3-NF-κB-shRNA cells cultured in media containing normal FBS (G) for 72 hours. Cell viability is presented relative to that of mock treatment or control-shRNA. Wound-healing assay was performed in: UMUC3 cells cultured in media containing charcoal-stripped FBS (CS-FBS) with ethanol (mock), BA (10 μM), or PAR (10 μM) (B); UMUC3 cells cultured in media containing CS-FBS with DHT (10 nM) and ethanol (mock), BA (10 μM), or PAR (10 μM) (D); UMUC3 cells cultured in media containing normal FBS with ethanol (mock), TNF-α (20 ng/mL), or DHMEQ (10 µg/mL) (F); or UMUC3-control-shRNA or UMUC3-NF-κB-shRNA cells cultured in media containing normal FBS (H). The cells grown to confluence were gently scratched and the wound area was measured after 18-hour culture. The migration determined by the rate of cells filling the wound area is presented relative to that of each line with mock treatment or control-shRNA. Each value represents the mean (+SD) from three independent experiments. *P<0.05 (vs. mock treatment or control-shRNA by Student''s t-test).
Supplementary Figure S3 from Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling
Authors: Inoue Satoshi , Ide Hiroki , Mizushima Taichi , Jiang Guiyang , Netto George J. , Gotoh Momokazu , Miyamoto Hiroshi
Published: April 2023

Effects of NF-κB activation/inhibition on the expression of NF-κB and its downstream targets as well as AR in bladder cancer cells. Western blotting of NF-κB/p65, p-NF-κB/p65, and AR, using proteins extracted from UMUC3 cells cultured with ethanol (mock), TNF-α (20 ng/mL), or DHMEQ (15 µg/mL) for 6 hours. Total proteins (A) or separate nuclear and cytoplasmic protein fractions (B) were immunoblotted for NF-κB/p65, p-NF-κB/p65, and AR. GAPDH and Lamin B1 served as loading controls of total/cytoplasmic and nuclear proteins, respectively. Densitometry values for NF-κB/p-NF-κB/AR standardized by GAPDH/Lamin B1 that are relative to those of mock treatment are included below the lanes. (C) Quantitative real-time RT-PCR of c-myc, cyclin D1, and MMP-9 in UMUC3 cells cultured with ethanol (mock), BA (10 μM), or PAR (10 μM) for 24 hours. Expression of each gene was normalized to that of GAPDH. Transcription amount is presented relative to that of mock-treated cells. Each value represents the mean (+SD) from three independent experiments. *P<0.05 (vs. mock treatment by Student's t-test).
Supplementary Figure S2 from Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling
Authors: Inoue Satoshi , Ide Hiroki , Mizushima Taichi , Jiang Guiyang , Netto George J. , Gotoh Momokazu , Miyamoto Hiroshi
Published: April 2023

Effects of TNF-α/DHMEQ on the expression of NF-κB and AR as well as neoplastic transformation of urothelial cells. Western blotting of NF-κB/p65, p-NF-κB/p65, and AR, using proteins extracted from SVHUC-AR cells cultured with ethanol (mock), TNF-α (20 ng/mL), or DHMEQ (15 µg/mL) for 6 hours. Total proteins (A) or separate nuclear and cytoplasmic protein fractions (B) were immunoblotted for NF-κB/p65, p-NF-κB/p65, and AR. GAPDH and Lamin B1 served as loading controls of total/cytoplasmic and nuclear proteins, respectively. Densitometry values for NF-κB/p-NF-κB/AR standardized by GAPDH/Lamin B1 that are relative to those of mock treatment are included below the lanes. SVHUC-AR cells exposed to MCA and subsequently treated with ethanol (mock), TNF-α (20 ng/mL), or DHMEQ (5 µg/mL) for 6 weeks were seeded for MTT assay (C; cultured for 7 days). TNF-α or DHMEQ was not treated during the assay. Cell viability is presented relative to that in mock-treated cells. Each value represents the mean (+SD) from three independent experiments. *P<0.05 (vs. mock treatment by Student's t-test). SVHUC-AR-control-shRNA or SVHUC-AR-NF-κB-shRNA cells exposed to MCA and subsequently cultured for 6 weeks were seeded for MTT assay (D; cultured for 7 days). Cell viability is presented relative to that in control-shRNA cells. Each value represents the mean (+SD) from three independent experiments. *P<0.05 (vs. control-shRNA by Student's t-test).
Supplementary Figure Legends from Lack of Constitutively Active DNA Repair Sensitizes Glioblastomas to Akt Inhibition and Induces Synthetic Lethality with Radiation Treatment in a p53-Dependent Manner
Authors: Palanichamy Kamalakannan , Patel Disha , Jacob John R. , Litzenberg Kevin T. , Gordon Nicolaus , Acus Kirstin , Noda Shin-ei , Chakravarti Arnab
Published: April 2023

Supplementary Figure Legends
Supplementary Table S2 from PMP22 Regulates Self-Renewal and Chemoresistance of Gastric Cancer Cells
Authors: Cai Wangyu , Chen Gang , Luo Qicong , Liu Jun , Guo Xiaofeng , Zhang Tian , Ma Fei , Yuan Liang , Li Boan , Cai Jianchun
Published: April 2023

The complete lists of genes significantly altered by shRNA KD of PMP22.
Table S1 from Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β
Authors: Lau Wen Min , Teng Eileen , Huang Kie Kyon , Tan Jin Wei , Das Kakoli , Zang Zhijiang , Chia Tania , Teh Ming , Kono Koji , Yong Wei Peng , Shabbir Asim , Tay Amy , Phua Niam Sin , Tan Patrick , Chan Shing Leng , So Jimmy Bok Yan
Published: April 2023

Clinicopathological features of GAGA patients
Figure S6 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
Authors: Koganemaru Shigehiro , Kuboki Yasutoshi , Koga Yoshikatsu , Kojima Takashi , Yamauchi Mayumi , Maeda Naoyuki , Kagari Takashi , Hirotani Kenji , Yasunaga Masahiro , Matsumura Yasuhiro , Doi Toshihiko
Published: April 2023

Body weight changes of tumor xenograft mice under treatment with each drug in the SW620 tumor xenograft model.
Figure S5 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
Authors: Koganemaru Shigehiro , Kuboki Yasutoshi , Koga Yoshikatsu , Kojima Takashi , Yamauchi Mayumi , Maeda Naoyuki , Kagari Takashi , Hirotani Kenji , Yasunaga Masahiro , Matsumura Yasuhiro , Doi Toshihiko
Published: April 2023

Body weight changes of tumor xenograft mice under treatment with each drug in the DiFi tumor xenograft model.
Figure S3 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
Authors: Koganemaru Shigehiro , Kuboki Yasutoshi , Koga Yoshikatsu , Kojima Takashi , Yamauchi Mayumi , Maeda Naoyuki , Kagari Takashi , Hirotani Kenji , Yasunaga Masahiro , Matsumura Yasuhiro , Doi Toshihiko
Published: April 2023

Body weight changes in tumor-xenografted mice treated with U3-1402.
Figure S1 from Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response
Authors: Min Ahrum , Jang Hyemin , Kim Seongyeong , Lee Kyung-Hun , Kim Debora Keunyoung , Suh Koung Jin , Yang Yaewon , Elvin Paul , O'Connor Mark J. , Im Seock-Ah
Published: April 2023

Androgen receptor expression in breast cancer cell lines
Figure S6 from TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer
Authors: Principe Daniel R. , Park Alex , Dorman Matthew J. , Kumar Sandeep , Viswakarma Navin , Rubin Jonathan , Torres Carolina , McKinney Ronald , Munshi Hidayatullah G. , Grippo Paul J. , Rana Ajay
Published: April 2023

Figure S6 shows the survival of vehicle and single agent control mice.
Figure S3 from TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer
Authors: Principe Daniel R. , Park Alex , Dorman Matthew J. , Kumar Sandeep , Viswakarma Navin , Rubin Jonathan , Torres Carolina , McKinney Ronald , Munshi Hidayatullah G. , Grippo Paul J. , Rana Ajay
Published: April 2023

Figure S3 shows that tumor bearing mice treated with both Galunisertib and anti-PD-1 display increased PD-L1 expression, and have improved weight gain compared to single agent or vehicle controls.
Supplementary Methods and Supplementar Figures S1-S13 from Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin
Authors: Sima Livia Elena , Yakubov Bakhtiyor , Zhang Sheng , Condello Salvatore , Grigorescu Arabela A. , Nwani Nkechiyere G. , Chen Lan , Schiltz Gary E. , Arvanitis Constandina , Zhang Zhong-Yin , Matei Daniela
Published: April 2023

Materials, methods; Figure S1. 1H NMR spectrum of MT-1; Figure S2. 1H NMR spectrum of MT-2; Figure S3. 1H NMR spectrum of MT-3; Figure S4. 1H NMR spectrum of MT-4; Figure S5. 1H NMR spectrum of MT-5; Figure S6. 1H NMR spectrum of MT-6; Figure S7. Enthalpy kinetics of MT-4 -TG2 interaction as measured by Isothermal Titration Calorimetry (ITC); Figure S8. Effects of TG-53 and MT-4 on TGase activity; Figure S9. TIRF analysis of β1 integrin receptors distribution upon cell treatment with SMIs at the indicated concentrations and adhesion onto FN coated plates; Figure S10. Flow cytometry analysis of integrin β1 plasma membrane expression; Figure S11. Dose response effects induced by TG2-FN inhibitors on FAK phosphorylation; Figure S12. Experimental design for in vivo assay testing the activity of MT4; Figure S13. Cell cycle distribution and apoptosis of OVCAR5 cells primed with MT-4 or TG53 for 72 hours before treatment with paclitaxel (PTX).
Supplementary Figure 1 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Authors: Tomita Yusuke , Kurozumi Kazuhiko , Yoo Ji Young , Fujii Kentaro , Ichikawa Tomotsugu , Matsumoto Yuji , Uneda Atsuhito , Hattori Yasuhiko , Shimizu Toshihiko , Otani Yoshihiro , Oka Tetsuo , Kaur Balveen , Date Isao
Published: April 2023

Supplementary Figure 1 shows Evaluation of glioma cells infected by oncolytic virus and conditioned medium.
Supplementary Figure S8 from IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy
Authors: Beha Nadine , Harder Markus , Ring Sarah , Kontermann Roland E. , Müller Dafne
Published: April 2023

Activity of monomeric and oligomeric RD_IL-15_scFv_scGITRL
Supplementary Figure S7 from IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy
Authors: Beha Nadine , Harder Markus , Ring Sarah , Kontermann Roland E. , Müller Dafne
Published: April 2023

IL-15 activity of mono- and bivalent IL-15 fusion proteins
Supplementary Figure S6 from IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy
Authors: Beha Nadine , Harder Markus , Ring Sarah , Kontermann Roland E. , Müller Dafne
Published: April 2023

Functional analysis of fusion proteins with mouse scGITRL
Supplementary Figure S1 from IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy
Authors: Beha Nadine , Harder Markus , Ring Sarah , Kontermann Roland E. , Müller Dafne
Published: April 2023

Sequence
Supplementary Figures 1-7 from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
Authors: Weisberg Ellen , Halilovic Ensar , Cooke Vesselina G. , Nonami Atsushi , Ren Tao , Sanda Takaomi , Simkin Irene , Yuan Jing , Antonakos Brandon , Barys Louise , Ito Moriko , Stone Richard , Galinsky Ilene , Cowens Kristen , Nelson Erik , Sattler Martin , Jeay Sebastien , Wuerthner Jens U. , McDonough Sean M. , Wiesmann Marion , Griffin James D.
Published: April 2023

Supplementary Figures 1-7 Supplementary Figure 1. Amplification and sequencing primers used for genotyping of p53 in AML patient samples. Supplementary Figure 2. Apoptosis data corresponding to representative bar graphs shown in Figure 1C. Supplementary Figure 3. Cell cycle analysis data corresponding to representative bar graphs shown in Figure 1D. Supplementary Figure 4. Inhibition of growth of mutant FLT3-positive AML cells by CGM097. Supplementary Figure 5. Potentiation of effects of PKC412 by CGM097 against mutant FLT3-positive AML cells. Supplementary Figure 6. Potentiation of effects of AC220 by CGM097 against mutant FLT3-positive AML cells cultured in the absence and the presence of cytoprotective SCM. Supplementary Figure 7 (A-F). Apoptosis data corresponding to representative bar graphs shown in Figure 5C. Supplementary Figure 7 (G-L). Apoptosis data corresponding to representative bar graphs shown in Figure 5C. Supplementary Figure 7 (M-R). Apoptosis data corresponding to representative bar graphs shown in Figure 5C.
Supplementary Figure legends from Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model
Authors: Curley Michael D. , Sabnis Gauri J. , Wille Lucia , Adiwijaya Bambang S. , Garcia Gabriela , Moyo Victor , Kazi Armina A. , Brodie Angela , MacBeath Gavin
Published: April 2023

Brief descriptions of the supplementary figure data provided
Supplementary Figure 6 from Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model
Authors: Curley Michael D. , Sabnis Gauri J. , Wille Lucia , Adiwijaya Bambang S. , Garcia Gabriela , Moyo Victor , Kazi Armina A. , Brodie Angela , MacBeath Gavin
Published: April 2023

Dosing everolimus in combination with letrozole and seribantumab causes weight loss in mice
Table S2 from HSP90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors
Authors: Proia David A. , Smith Donald L. , Zhang Junyi , Jimenez John-Paul , Sang Jim , Ogawa Luisa Shin , Sequeira Manuel , Acquaviva Jaime , He Suqin , Zhang Chaohua , Khazak Vladimir , Astsaturov Igor , Inoue Takayo , Tatsuta Noriaki , Osman Sami , Bates Richard C. , Chimmanamada Dinesh , Ying Weiwen
Published: April 2023

Physicochemical properties of HSP90 inhibitor and inhibitor-conjugates
Supplementary Figures 1-5 from Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
Authors: Davies Barry R. , Guan Nin , Logie Armelle , Crafter Claire , Hanson Lyndsey , Jacobs Vivien , James Neil , Dudley Philippa , Jacques Kelly , Ladd Brendon , D'Cruz Celina M. , Zinda Michael , Lindemann Justin , Kodaira Makoto , Tamura Kenji , Jenkins Emma L.
Published: April 2023

Supplementary Figure 1: Expression of signalling proteins in MCF10A-AKT1WT and MCF10A-AKT1E17K cells grown in the presence or absence of doxycycline; Supplementary Figure 2: Colony formation in soft agar using MCF10A cells expressing AKT1E17K, AKT1WT, ERBB2V659E or RFP under a tet-inducible promoter in the presence or absence of 1 μg/mL doxycycline; Supplementary Figure 3: Histograms showing the frequencies of colonies of various diameters; Supplementary Figure 4: Detection of AKT1E17K mutation in HBC-x2 xenograft tissue; Supplementary Figure 5: Effect of AKT inhibitors, AZD5363 and MK-2206 on AKT pathway biomarkers and growth of MGH-U3 cells in vitro.
Supplementary Table 2 from The RNA-Binding Protein HuR Confers Oxaliplatin Resistance of Colorectal Cancer By Upregulating CDC6
Authors: Cai Jian , Wang Huaiming , Jiao Xiaodong , Huang Rongkang , Qin Qiyuan , Zhang Jianwei , Chen Honglei , Feng Dan , Tian Xin , Wang Hui
Published: April 2023

CDC6 staining and clinicopathological characteristics of 160 colon cancer patients
Supplementary Table 1 from The RNA-Binding Protein HuR Confers Oxaliplatin Resistance of Colorectal Cancer By Upregulating CDC6
Authors: Cai Jian , Wang Huaiming , Jiao Xiaodong , Huang Rongkang , Qin Qiyuan , Zhang Jianwei , Chen Honglei , Feng Dan , Tian Xin , Wang Hui
Published: April 2023

HuR staining and clinicopathological characteristics of 160 colon cancer patients
Figure S4 from Reduction of Muscle-Invasive Tumors by Photodynamic Therapy with Tetrahydroporphyrin-Tetratosylat in an Orthotopic Rat Bladder Cancer Model
Authors: Berndt-Paetz Mandy , Schulze Philipp , Stenglein Philipp C. , Weimann Annett , Wang Qiang , Horn Lars-Christian , Riyad Yasser M. , Griebel Jan , Hermann Ralf , Glasow Annegret , Stolzenburg Jens-Uwe , Neuhaus Jochen
Published: April 2023

Figure S4 shows cytotoxic effects of in vitro PDT determined by cell-based assays.
Figure S6 from Monoclonal Antibody Targeting Sialyl-di-Lewisa–Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential
Authors: Tivadar Silvana T. , McIntosh Richard S. , Chua Jia Xin , Moss Robert , Parsons Tina , Zaitoun Abed M. , Madhusudan Srinivasan , Durrant Lindy G. , Vankemmelbeke Mireille
Published: April 2023

Complete amino acid and nucleotide sequence of mouse FG129/29 heavy and light chain
Figure S5 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
Authors: Mao Fengyi , Li Jie , Luo Qian , Wang Ruixin , Kong Yifan , Carlock Colin , Liu Zian , Elzey Bennet D. , Liu Xiaoqi
Published: April 2023

A proposed working model
Supplementary Tables S1-S2 and Figures S1-S11 from ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2−/− Ovarian Cancer Cells
Authors: Liu Lu , Cai Shurui , Han Chunhua , Banerjee Ananya , Wu Dayong , Cui Tiantian , Xie Guozhen , Zhang Junran , Zhang Xiaoli , McLaughlin Eric , Yin Ming , Backes Floor J. , Chakravarti Arnab , Zheng Yanfang , Wang Qi-En
Published: April 2023

Supplemental table S1 shows siRNA sequences. Table S2 shows primer sequences used for RTPCR. Figure S1 shows sensitivity of various cells to olaparib. Figure S2 shows the effect of olaparib on ALDHbr population. Figure S3 shows expression of ALDH isoforms at mRNA level. Figure S4 shows mRNA level of ALDH isoforms in PARPi-resistance cancer cells. Figure S5 shows the effect of ALDH1A1 expression on the sensitivity of EOC cells to olaparib. Figure S6 shows DNA repair ability in ALDH+ cells. Figure S7 shows the effect of ALDH1A1 on homologous recombination repair. Figure S8 shows the effect of NCT-501 on cell viability and ALDH activity. Figure S9 shows BRCA2 expression in various EOC cells. Figure S10 shows the combined effect of olaparib and NCT-501 on BRCA2-wt cells. Figure S11 shows the effect of NCT-501 on DNA repair in PARPi-resistant cells.
Supplementary Fig. S5 from A Multifunctional Therapy Approach for Cancer: Targeting Raf1- Mediated Inhibition of Cell Motility, Growth, and Interaction with the Microenvironment
Authors: Zhang Limin , Pattanayak Abhinandan , Li Wenqi , Ko Hyun-Kyung , Fowler Graham , Gordon Ryan , Bergan Raymond
Published: April 2023

Supplementary Fig. S5 shows that small molecule Raf1 inhibitors inhibit osteoclast function.
Supplemental Figure 4 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Authors: Lemberg Kathryn M. , Zhao Liang , Wu Ying , Veeravalli Vijayabhaskar , Alt Jesse , Aguilar Joanna Marie H. , Dash Ranjeet P. , Lam Jenny , Tenora Lukáš , Rodriguez Chabely , Nedelcovych Michael T. , Brayton Cory , Majer Pavel , Blakeley Jaishri O. , Rais Rana , Slusher Barbara S.
Published: April 2023

Supplemental Figure 4: Weight changes in non-tumored NPcis mice over one month of daily JHU395 dosing.
Supplementary Table S5 from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
Authors: Merlino Giuseppe , Fiascarelli Alessio , Bigioni Mario , Bressan Alessandro , Carrisi Corrado , Bellarosa Daniela , Salerno Massimiliano , Bugianesi Rossana , Manno Rosanna , Bernadó Morales Cristina , Arribas Joaquin , Bisht Arnima , Kaplan Angelo , Boyd Robert , Do Uyen T. , Swaminathan Sudha , Attanasio Nickolas , Lou San Lin , Dusek Rachel L. , Ackroyd James E. , Pham Phuoc Huy , Awdew Rahel , Aud Dee , Trang Michael , Lynch Carmel M. , Terrett Jonathan , Wilson Keith E. , Rohlff Christian , Manzini Stefano , Pellacani Andrea , Binaschi Monica
Published: April 2023

Supplementary Table S5: Microscopic IHC staining for CD205 in different cynomolgus tissues after treatment with MEN1309/OBT076. Staining: 1, minimal (+, rare cells with low staining intensity); 2, slight/moderate (++, many cells with medium/high staining intensity); 3, marked (+++, significant numbers of cells with high staining intensity); 0, negative (no stained cells); -, no background present; tm, tissue missing; lp, lesion present; p, background staining present; N/A, not applicable.
Supplementary Figure 1-7 from Antiproliferative Effects of Monoclonal Antibodies against (Pro)Renin Receptor in Pancreatic Ductal Adenocarcinoma
Authors: Rahman Asadur , Matsuyama Makoto , Ebihara Akio , Shibayama Yuki , Hasan Arif Ul , Nakagami Hironori , Suzuki Fumiaki , Sun Jiao , Kobayashi Tomoe , Hayashi Hiroki , Nakano Daisuke , Kobara Hideki , Masaki Tsutomu , Nishiyama Akira
Published: April 2023

Supplementary Figures and legends
Supplementary Figure 1 from Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages
Authors: Iwanowycz Stephen , Wang Junfeng , Hodge Johnie , Wang Yuzhen , Yu Fang , Fan Daping
Published: April 2023

Emodin inhibits lung metastasis of breast tumors
Supplementary Table 1 from Improved Tumor-Specific Drug Accumulation by Polymer Therapeutics with pH-Sensitive Drug Release Overcomes Chemotherapy Resistance
Authors: Heinrich Anne-Kathrin , Lucas Henrike , Schindler Lucie , Chytil Petr , Etrych Tomáš , Mäder Karsten , Mueller Thomas
Published: April 2023

Physico-chemical characterization of pHPMA conjugates
Supplementary Figure 2 from Improved Tumor-Specific Drug Accumulation by Polymer Therapeutics with pH-Sensitive Drug Release Overcomes Chemotherapy Resistance
Authors: Heinrich Anne-Kathrin , Lucas Henrike , Schindler Lucie , Chytil Petr , Etrych Tomáš , Mäder Karsten , Mueller Thomas
Published: April 2023

Development of mouse body weight under respective therapy over time.
Figure S1 from AKT Inhibition Modulates H3K4 Demethylase Levels in PTEN-Null Prostate Cancer
Authors: Khan Mohammad Imran , Hamid Abid , Rath Suvasmita , Ateeq Bushra , Khan Qateeb , Siddiqui Imtiaz A. , Adhami Vaqar Mustafa , Choudhry Hani , Zamzami Mazin A. , Mukhtar Hasan
Published: April 2023

Supplementary Figure S1: showing H&E staining of PTEN wild type (A) and knock out mice treated with vehicle (B) and perifosine (C).
Supplemental Figure S4 from Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors
Authors: Hedrick Erik , Li Xi , Safe Stephen
Published: April 2023

Penfluridol as an NR4A1 anatagonist.
Supplementary Table 1 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Authors: Black Jonathan , Menderes Gulden , Bellone Stefania , Schwab Carlton L. , Bonazzoli Elena , Ferrari Francesca , Predolini Federica , De Haydu Christopher , Cocco Emiliano , Buza Natalia , Hui Pei , Wong Serena , Lopez Salvatore , Ratner Elena , Silasi Dan-Arin , Azodi Masoud , Litkouhi Babak , Schwartz Peter E. , Goedings Peter , Beusker Patrick H. , van der Lee Miranda M.C. , Timmers C. Marco , Dokter Wim H.A. , Santin Alessandro D.
Published: April 2023

Cathepsin B expression. Expression of CTSB vs GAPDH in the primary USC cell lines used for in in vitro validation experiments.
Supplemental Figure S1 from Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors
Authors: Hedrick Erik , Li Xi , Safe Stephen
Published: April 2023

Supplemental Figure S1. Role of ROS and cMyc in penfluridol-induced responses. (A) Induction of ROS. Cells were treated with penfluridol alone or in combination with GSH, and ROS was determined after 24 hr. (B) Role of ROS in penfluridol-induces responses. Cells were treated with penfluridol alone or in combination with NAC for 24 hr, and whole cell lysates were analyzed by western blots. (C) cMyc knockdown. Cells were transfected with siCtl (control) or siMyc(#2), and whole cell lysates were analyzed by western blots.
Supplementary Table 8 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Authors: Miller Rowan E. , Brough Rachel , Bajrami Ilirjana , Williamson Chris T. , McDade Simon , Campbell James , Kigozi Asha , Rafiq Rumana , Pemberton Helen , Natrajan Rachel , Joel Josephine , Astley Holly , Mahoney Claire , Moore Jonathan D. , Torrance Chris , Gordan John D. , Webber James T. , Levin Rebecca S. , Shokat Kevan M. , Bandyopadhyay Sourav , Lord Christopher J. , Ashworth Alan
Published: April 2023

Pearson's correlation and Z prime values for isogenic cell lines demonstrating robust reproducibility and dynamic range from the high-throughput drug screen, see also Figure 1
Supplementary table 1 from Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma
Authors: Meerang Mayura , Bérard Karima , Felley-Bosco Emanuela , Lauk Olivia , Vrugt Bart , Boss Andreas , Kenkel David , Broggini-Tenzer Angela , Stahel Rolf A. , Arni Stephan , Weder Walter , Opitz Isabelle
Published: April 2023

List of primers for quantitative real time PCR
Supplementary Table 7 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Authors: Miller Rowan E. , Brough Rachel , Bajrami Ilirjana , Williamson Chris T. , McDade Simon , Campbell James , Kigozi Asha , Rafiq Rumana , Pemberton Helen , Natrajan Rachel , Joel Josephine , Astley Holly , Mahoney Claire , Moore Jonathan D. , Torrance Chris , Gordan John D. , Webber James T. , Levin Rebecca S. , Shokat Kevan M. , Bandyopadhyay Sourav , Lord Christopher J. , Ashworth Alan
Published: April 2023

Results from the high throughput drug screen in the non-isogenic OCCC cell line panel, see also Figure 1
Supplementary Table 5 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Authors: Miller Rowan E. , Brough Rachel , Bajrami Ilirjana , Williamson Chris T. , McDade Simon , Campbell James , Kigozi Asha , Rafiq Rumana , Pemberton Helen , Natrajan Rachel , Joel Josephine , Astley Holly , Mahoney Claire , Moore Jonathan D. , Torrance Chris , Gordan John D. , Webber James T. , Levin Rebecca S. , Shokat Kevan M. , Bandyopadhyay Sourav , Lord Christopher J. , Ashworth Alan
Published: April 2023

ARID1A mutation status in OCCC panel determined by whole exome sequencing
Supplementary Figure S2 from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Authors: Andreev Julian , Thambi Nithya , Perez Bay Andres E. , Delfino Frank , Martin Joel , Kelly Marcus P. , Kirshner Jessica R. , Rafique Ashique , Kunz Arthur , Nittoli Thomas , MacDonald Douglas , Daly Christopher , Olson William , Thurston Gavin
Published: April 2023

Proteasomal degradation inhibitors, Bortezomib and Lactacystin had little or no effect on PRLR turnover.
Table S1 from TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
Authors: Zaman Guido J.R. , de Roos Jeroen A.D.M. , Libouban Marion A.A. , Prinsen Martine B.W. , de Man Jos , Buijsman Rogier C. , Uitdehaag Joost C.M.
Published: April 2023

Relation between TTK inhibitor sensitivity and CTNNB1 mutant status on the basis of Oncolines data
Supplementary Video S4. Interphase microtubule dynamics in HeLa-EB1-GFP treated with 6-AA (2.5 nM). from 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells
Authors: Levrier Claire , Sadowski Martin C. , Rockstroh Anja , Gabrielli Brian , Kavallaris Maria , Lehman Melanie , Davis Rohan A. , Nelson Colleen C.
Published: April 2023

EB1-GFP was imaged by spinning disk microscopy (1 image/s for 1 min). EB1 comets followed irregular and short trajectories. Scale bar=10 Âµm.
Supplementary Video S2.Time-lapse microscopy of HeLa-H2B-GFP cells treated with 6-AA (2.5, 5 and 10 nM). from 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells
Authors: Levrier Claire , Sadowski Martin C. , Rockstroh Anja , Gabrielli Brian , Kavallaris Maria , Lehman Melanie , Davis Rohan A. , Nelson Colleen C.
Published: April 2023

HeLa-H2B-GFP cells were imaged using an Olympus IX81 (1 image/5 min for 24 h). Top panels: brightfield, bottom panels: GFP channel. 6-AA increased in a concentration-dependent manner mitotic duration, leading to cell death or asymmetric division. Scale bar=20 Âµm.
Figure S2 from TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
Authors: Zaman Guido J.R. , de Roos Jeroen A.D.M. , Libouban Marion A.A. , Prinsen Martine B.W. , de Man Jos , Buijsman Rogier C. , Uitdehaag Joost C.M.
Published: April 2023

Relationship TTK inhibitor sensitivity and cancer gene mutant status
Supplementary figure S5 from Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non–Small Cell Lung Cancer
Authors: Feng Jianguo , Zhang Shirong , Wu Kan , Wang Bing , Wong Jeffrey Y.C. , Jiang Hong , Xu Rujun , Ying Lisha , Huang Haixiu , Zheng Xiaoliang , Chen Xufeng , Ma Shenglin
Published: April 2023

SAHA induces differentiation of stem cell-like cancer cells and inhibits cancer cell invasion of H1299 cell line
Supplementary figure S4 from Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non–Small Cell Lung Cancer
Authors: Feng Jianguo , Zhang Shirong , Wu Kan , Wang Bing , Wong Jeffrey Y.C. , Jiang Hong , Xu Rujun , Ying Lisha , Huang Haixiu , Zheng Xiaoliang , Chen Xufeng , Ma Shenglin
Published: April 2023

SAHA induces differentiation of stem cell-like cancer cells in H460 cell line
Supplementary figure S2 from Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non–Small Cell Lung Cancer
Authors: Feng Jianguo , Zhang Shirong , Wu Kan , Wang Bing , Wong Jeffrey Y.C. , Jiang Hong , Xu Rujun , Ying Lisha , Huang Haixiu , Zheng Xiaoliang , Chen Xufeng , Ma Shenglin
Published: April 2023

Effects of SAHA and Cisplatin on IR-induced DNA damage repair in human lung cancer cells
Table 2 from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
Authors: Weeden Clare E. , Holik Aliaksei Z. , Young Richard J. , Ma Stephen B. , Garnier Jean-Marc , Fox Stephen B. , Antippa Phillip , Irving Louis B. , Steinfort Daniel P. , Wright Gavin M. , Russell Prudence A. , Ritchie Matthew E. , Burns Christopher J. , Solomon Benjamin , Asselin-Labat Marie-Liesse
Published: April 2023

Supplementary Table S2: GO term enrichment analysis of differentially expressed genes between t1 and t0, overlapping in PDX 788, 926, 792
Supplementary Materials from Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer
Authors: Grüner Barbara M. , Winkelmann Isabel , Feuchtinger Annette , Sun Na , Balluff Benjamin , Teichmann Nicole , Herner Alexander , Kalideris Evdokia , Steiger Katja , Braren Rickmer , Aichler Michaela , Esposito Irene , Schmid Roland M. , Walch Axel , Siveke Jens T.
Published: April 2023

Supplemental material and methods file
Supplementary Fig S1-S5 from The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase
Authors: Okada-Iwasaki Ryoko , Takahashi Yuichi , Watanabe Yasuo , Ishida Hiroshi , Saito Jun-ichi , Nakai Ryuichiro , Asai Akira
Published: April 2023

Supplementary Fig. S1: A, CTNNB1 siRNAs suppress the target gene and B, the target protein. C, CTNNB1 siRNAs inhibit reporter activity and D, change the expression of Wnt/β-catenin downstream genes.; Supplementary Fig. S2: A, K-756 does not inhibit cell growth of DLD-1/TCF-Luc cells. B, CTNNB1 siRNAs suppress the target gene in COLO 320DM and SW403 cells. C, K-050, and inactive analogue of K-756, does not inhibit COLO 320DM cells.; Supplementary Fig. S3: A, XAV939 and B, IWR-1 stabilize Axins and suppress active β-catenin in COLO 320DM and SW403 cells. C, The Axin stabilization and active β-catenin levels are higher in K-756-treated cells than XAV939-treated cells.; Supplementary Fig. S4: A, PK data of K-756. B, LGR5 inhibition by K-756 in in vitro. Time course PD experiments of C, FGF20, D, LGR5 and E, reporter activity in tumors of K-756-administered mice.; Supplementary Fig. S5: A, Axin and active β-catenin expression in K-756-treated PC-9 and NCI-H322 cells. B, The expression change of Wnt/β-catenin downstream gene in K-756-treated NCI-H322 cells.
Supplementary Information and Data from The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas
Authors: Peh Jessie , Fan Timothy M. , Wycislo Kathryn L. , Roth Howard S. , Hergenrother Paul J.
Published: April 2023

The supplementary information file contains details about primers used for this work, supplementary Figures S1-S8, supplementary Table S1, and results from cell line authentication and from mycoplasma testing.
Supplementary Table S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Authors: Eigenmann Miro J. , Frances Nicolas , Hoffmann Gerhard , Lavé Thierry , Walz Antje-Christine
Published: April 2023

Presents the estimated parameter values derived from the biomarker short term modeling.
Table S1 from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
Authors: Miller Michael L. , Fishkin Nathan E. , Li Wei , Whiteman Kathleen R. , Kovtun Yelena , Reid Emily E. , Archer Katie E. , Maloney Erin K. , Audette Charlene A. , Mayo Michele F. , Wilhelm Alan , Modafferi Holly A. , Singh Rajeeva , Pinkas Jan , Goldmacher Victor , Lambert John M. , Chari Ravi V.J.
Published: April 2023

Effect of substitution of an indolino moiety (6) for a pyrrolo group (SJG-136) on in vitro potency
Supplementary Table 1 from Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
Authors: Chang Chien-Hsing , Wang Yang , Zalath Maria , Liu Donglin , Cardillo Thomas M. , Goldenberg David M.
Published: April 2023

Relative mRNA levels of ABCG2 determined by RT-qPCR
Supplementary Methods from Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform
Authors: Morry Jingga , Ngamcherdtrakul Worapol , Gu Shenda , Reda Moataz , Castro David J. , Sangvanich Thanapon , Gray Joe W. , Yantasee Wassana
Published: April 2023

Detailed description of the methods used in the manuscript.
Figure S4 from Alkylating Agent–Induced NRF2 Blocks Endoplasmic Reticulum Stress–Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis
Authors: Zanotto-Filho Alfeu , Masamsetti V. Pragathi , Loranc Eva , Tonapi Sonal S. , Gorthi Aparna , Bernard Xavier , Gonçalves Rosângela Mayer , Moreira José C.F. , Chen Yidong , Bishop Alexander J.R.
Published: April 2023

Box-plot representation of NRF2 target gene expressions and NRF2 Pathway Signature Expression in lung and head and neck carcinomas carrying different NRF2 activating genetic alterations; Mutation Enrichment Analysis (MEA) showing that mutant NFE2L2 is associated with increased expression of the NRF2 targets in head and neck squamous cell carcinomas. Also includes cell viability experiments in A549 cells.
Supplementary Figure S4. Overexpression of RIP2 wild type or RIP2 (S176E) induces the resistance to GSK2118436 in MV522 cells. from EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines
Authors: Kim Sung-Moo , Kim Hwan , Jang Kang Won , Kim Min Hwan , Sohn Jinyoung , Yun Mi Ran , Kang Han Na , Kang Chan Woo , Kim Hye Ryun , Lim Sun Min , Moon Yong Wha , Kim Joo Hang , Paik Soonmyung , Cho Byoung Chul
Published: April 2023

A, Cells were transfected for 24 h with EGFP-C1 vector, plasmids encoding RIP2-GFP, or RIP2 (S176E)-GFP (which is phosphorylated form constitutively), respectively, and treated with or without GSK2118436 for 48 h. Lysates were probed with the indicated antibodies. B, Cells were transfected for 24 h with EGFP-C1 vector, RIP2-GFP or RIP2 (S176E)-GFP, respectively, and treated with or without GSK2118436 at the indicated concentration for 14 days before staining with crystal violet. Data are normalized to GSK2118436 or control and are displayed as mean {plus minus} SEM (n = 3, ***P < 0.001).
Suppl. Figure 3 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
Authors: Wengner Antje M. , Siemeister Gerhard , Koppitz Marcus , Schulze Volker , Kosemund Dirk , Klar Ulrich , Stoeckigt Detlef , Neuhaus Roland , Lienau Philip , Bader Benjamin , Prechtl Stefan , Raschke Marian , Frisk Anna-Lena , von Ahsen Oliver , Michels Martin , Kreft Bertolt , von Nussbaum Franz , Brands Michael , Mumberg Dominik , Ziegelbauer Karl
Published: April 2023

Effect of BAY 1161909 in monotherapy on the frequencies of peripheral blood reticulocytes and micronuclei-harboring reticulocytes in nude mice
Supplemental Figures and Table from U1 Adaptors Suppress the KRAS-MYC Oncogenic Axis in Human Pancreatic Cancer Xenografts
Authors: Tsang Ashley T. , Dudgeon Crissy , Yi Lan , Yu Xin , Goraczniak Rafal , Donohue Kristen , Kogan Samuel , Brenneman Mark A. , Ho Eric S. , Gunderson Samuel I. , Carpizo Darren R.
Published: April 2023

Supplemental Figures 1-4 with figure legends and Supplemental Table
Table S1 from Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Authors: Yamaoka Toshimitsu , Ohmori Tohru , Ohba Motoi , Arata Satoru , Kishino Yasunari , Murata Yasunori , Kusumoto Sojiro , Ishida Hiroo , Shirai Takao , Hirose Takashi , Ohnishi Tsukasa , Sasaki Yasutsuna
Published: April 2023

Mutation analysis of EGFR and Met in PC-9, MET1000, DR2, DR4, and DR6 cells.
Supplementary Figure Legends from Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Authors: Yamaoka Toshimitsu , Ohmori Tohru , Ohba Motoi , Arata Satoru , Kishino Yasunari , Murata Yasunori , Kusumoto Sojiro , Ishida Hiroo , Shirai Takao , Hirose Takashi , Ohnishi Tsukasa , Sasaki Yasutsuna
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 6 from Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit
Authors: Geyer Philipp Emanuel , Maak Matthias , Nitsche Ulrich , Perl Markus , Novotny Alexander , Slotta-Huspenina Julia , Dransart Estelle , Holtorf Anne , Johannes Ludger , Janssen Klaus-Peter
Published: April 2023

The topoisomerase-inhibitor SN38 has similar effects on cell proliferation in Gb3 positive (St3051) or Gb3 negative (AGS) cells